CUSP06 exhibits excellent in vivo antitumor efficacy ranging from tumor growth inhibition to tumor regression in CDH6-high or -low cell-line-derived xenograft (CDX) or patient-derived xenograft (PDX) models from human ovarian, renal and uterine cancers as well as cholangiocarcinoma. Here, CDH6 is linked to neoplasm.